Carisma Therapeutics, Inc. (CARM)
OTCMKTS · Delayed Price · Currency is USD
0.0023
0.00 (0.00%)
At close: Aug 18, 2026
Carisma Therapeutics Revenue
Carisma Therapeutics had revenue of $45.25M in the quarter ending September 30, 2025, with 1,236.78% growth. This brings the company's revenue in the last twelve months to $52.63M, up 159.68% year-over-year. In the year 2024, Carisma Therapeutics had annual revenue of $19.63M with 31.59% growth.
Revenue (ttm)
52.63M
Revenue Growth
+159.68%
P/S Ratio
0.00
Revenue / Employee
1.14M
Employees
46
Market Cap
96.24K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.63M | 4.71M | 31.59% |
| Dec 31, 2023 | 14.92M | 5.09M | 51.71% |
| Dec 31, 2022 | 9.83M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Scorpius Holdings | 1.72M |
| GB Sciences | 97.24K |
| U.S. Stem Cell | 82.05K |
| Affymax | 42.00K |
| CNBX Pharmaceuticals | 40.64K |
Carisma Therapeutics News
- 2 months ago - ProKidney appoints Kenneth Locke as chief technical officer - TheFly
- 9 months ago - Carisma Therapeutics announces Nasdaq delisting, SEC deregistration - TheFly
- 9 months ago - Carisma Announces Delisting from Nasdaq and SEC Deregistration - PRNewsWire
- 10 months ago - Carisma Therapeutics Quarterly report: Q3 2025 - Filings
- 1 year ago - Why Is Carisma Therapeutics Stock (CARM) Up 165% Today? - TipRanks
- 1 year ago - Carisma Therapeutics Quarterly report: Q2 2025 - Filings
- 1 year ago - Carisma Therapeutics, OrthoCellix enter definitive merger agreement - TheFly
- 1 year ago - Carisma Therapeutics Stock (CARM) Retreats 35% After a Massive Rally - TipRanks